The efficacy and safety of enzalutamide for castrate-resistant prostate cancer patient showing disease progression after or during chemotherapy including docetaxel.
Not Applicable
- Conditions
- Castrate-resistant prostate cancer
- Registration Number
- JPRN-UMIN000023627
- Lead Sponsor
- Kumamoto University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- Male
- Target Recruitment
- 20
Inclusion Criteria
Not provided
Exclusion Criteria
1) contraindication for enzalutamide 2) history of seizure (including febrile seizure), loss of consciousness. 3) symptom of temporal brain ischemia or warning sign of seizure within a year 4) judged as inappropriate by the investigator.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method PSA response rate
- Secondary Outcome Measures
Name Time Method duration of PSA response Overall Survival QOL (FACT-P) Adverse Events